LOS ANGELES--(BUSINESS WIRE)-- KYTHERA Biopharmaceuticals, Inc. (KYTHERA), a privately held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, announced today that Keith Leonard, President and Chief Executive Officer, will present a corporate overview at the Leerink Swann 2012 Global Healthcare Conference in New York City.
|Leerink Swann 2012 Global Healthcare Conference|
|Wednesday, February 15, 2012|
|10:30 a.m. ET|
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market. KYTHERA’s lead clinical program, ATX-101, is focused on the reduction of submental (under the chin) fat. The company also has active research programs with focused interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.
KEYWORDS: United States North America California New York
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Other Health General Health